Hypothesis

Voice Function Exercises (VFE) improve presbyphonia not only by strengthening the thyroarytenoid (TA) muscle but also by reversing a maladaptive mitochondrial‑fibroblast signaling loop that drives lamina propria extracellular matrix (ECM) stiffening. Specifically, VFE‑induced mechanical strain activates integrin‑linked YAP/TAZ signaling in vocal fold fibroblasts, which upregulates PGC‑1α–dependent mitochondrial biogenesis in adjacent TA myofibers. Restored mitochondrial function reduces mtDNA‑derived danger‑associated molecular patterns (DAMPs), thereby attenuating fibroblast‑to‑myofibroblast transition and hyaluronan depletion. Consequently, ECM elasticity recovers and vocal efficiency rises.

Rationale

• Mitochondrial dysfunction in TA muscle is documented in denervation‑driven atrophy (miR‑142a‑5p → MFN1 suppression) [2]. This state releases mitochondrial DAMPs (e.g., mtDNA, formyl peptides) that can activate TLR9 on fibroblasts, promoting a pro‑fibrotic phenotype.
• Lamina propria ECM remodeling in presbyphonia shows reduced elastin, disordered collagen, and lost superficial layer volume [1]. Fibroblast activation is a plausible mechanistic link between muscle distress and matrix alteration.
• Voice therapy efficacy yields measurable MPT gains (~5–7 s) but unknown molecular mechanisms [5]. Mechanical loading during phonatory exercises is known to modulate YAP/TAZ nuclear translocation in mesenchymal cells, influencing ECM gene expression.
• Missing data: no human‑specific transcriptomic or proteomic maps of aging vocal fold fibroblasts or TA muscle exist [4]; thus the proposed cross‑talk remains untested.

Novel Mechanistic Insight

We propose that integrin‑αvβ3‑mediated mechanotransduction converts VFE‑generated cyclic strain into YAP/TAZ nuclear activity in fibroblasts. Nuclear YAP/TAZ complexes bind the promoter of PPARGC1A (PGC‑1α) in fibroblasts, secreting exosomes enriched with PGC‑1α mRNA and miRNAs that are taken up by TA myofibers. In the myofiber, PGC‑1α drives mitochondrial biogenesis, lowers ROS, and reduces DAMP release. Lower DAMP signaling diminishes fibroblast TGF‑β1/SMAD3 activation, decreasing α‑SMA expression and collagen cross‑linking while increasing hyaluronan synthase 2 (HAS2) activity. The net effect is a more compliant superficial lamina propria and improved vibratory efficiency.

Testable Predictions

1. Baseline biomarker stratification – Older adults with elevated circulating mtDNA or fibroblast‑derived exosomal miR‑142a‑5p will show poorer VFE adherence and smaller MPT improvements.
2. Intervention blockade – Pharmacologic inhibition of YAP/TAZ (e.g., verteporfin) or integrin‑αvβ3 (e.g., cilengitide) applied locally to the vocal fold will abolish VFE‑induced MPT gains despite unchanged TA muscle thickness.
3. Rescue experiment – Exogenous delivery of fibroblast‑derived exosomes enriched for PGC‑1α mRNA to denervated TA muscle in aged animal models will restore mitochondrial membrane potential (JC‑1 ratio) and increase MPT by ≥4 s, even without exercise.
4. ECM read‑out – Second‑harmonic generation imaging will reveal decreased collagen fiber alignment and increased elastin fragmentation in responders; non‑responders will retain pretreatment patterns.

Experimental Design (outline)

• Participants: 60 patients ≥65 y with presbyphonia (baseline MPT <10 s). Randomized to VFE (standard protocol) vs. sham vocal exercises.
• Interventions: Subset receives topical vocal‑fold injection of verteporfin (YAP/TAZ inhibitor) or placebo prior to each VFE session.
• Outcomes:
  • Primary: Change in MPT at 8 weeks.
  • Secondary: Serum mtDNA copy number, fibroblast exosome PGC‑1α content (qPCR), vocal‑fold biopsy (if ethically permissible) for YAP/TAZ nuclear staining, collagen/elastin ratio (SHG), HAS2 activity (ELISA).
• Analysis: Mixed‑effects models testing interaction between treatment, biomarker baseline, and MPT change; mediation analysis to assess whether changes in mitochondrial biomarkers mediate the VFE‑MPT relationship.

Falsifiability

If VFE improves MPT equally in patients with high vs. low baseline mtDNA, or if YAP/TAZ inhibition does not diminish the MPT benefit despite confirmed target engagement, the hypothesis would be refuted. Similarly, absence of exosomal PGC‑1α transfer or lack of ECM histologic changes in responders would falsify the proposed fibroblast‑muscle crosstalk.

Implications

Confirming this mechanism would shift presbyphonia research from descriptive correlations to a testable, targetable pathway. It would enable biomarker‑driven patient selection, rational combination therapies (e.g., mitochondrial supplements + VFE), and inspire drug development aimed at restoring vocal‑fold mitochondrial‑fibroblast homeostasis—addressing the current gap between statistically significant therapy trials and clinically meaningful voice restoration.